Lonafarnib in cancer therapy

Expert Opinion on Investigational Drugs

Volumn 15, Issue 6, 2006, Pages 709-719

  Morgillo, Floriana ^a   Lee, Ho Young ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Farnesyl transferase inhibitor; Lonafarnib; Ras; SCH 66336; Targeted therapy

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DYSKERIN; FLUOROURACIL; GEMCITABINE; IMATINIB; LONAFARNIB; LY 29400; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE B; RAS PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SCH 58500; TAXANE DERIVATIVE; TIPIFARNIB; VINCRISTINE; WORTMANNIN;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER THERAPY; CARDIOTOXICITY; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFUSION; CYTOTOXICITY; DEHYDRATION; DEPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; IC 50; INFECTION; LEUKOCYTE COUNT; LEUKOCYTOSIS; LUNG INSUFFICIENCY; LUNG NON SMALL CELL CANCER; MALAISE; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; QT PROLONGATION; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; REVIEW; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; SYNCOPE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; TUMOR GROWTH; TUMOR REGRESSION; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; HUMANS; LEUKEMIA; LUNG NEOPLASMS; PIPERIDINES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS;

EID: 33745274745     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.6.709     Document Type: Review

References (63)

1. BARBACID M: Ras genes. Ann. Rev. Biochem. (1987) 56:779-827.
2. BEAUPRE DM, KURZROCK R: Ras and leukemia: from basic mechanisms to gene-directed therapy. J. Clin. Oncol. (1999) 17(3):1071-1079.
3. McCORMICK F: Activators and effectors of ras p21 proteins. Curr. Opin. Genet. Dev. (1994) 4(1):71-76.
4. ALMOGUERA C, SHIBATA D, FORRESTER K et al.: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 53(4):549-554.
5. BOS JL: Ras oncogenes in human cancer: a review. Cancer Res. (1989) 49(17):4682-4689.
6. KHOSRAVI-FAR R, COX AD, KATO K, DER CJ: Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ. (1992) 3(7):461-469.
7. ADJEI AA, DAVIS JN, BRUZEK LM, ERLICHMAN C, KAUFMANN SH: Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines. Clin. Cancer Res. (2001) 7(5):1438-1445.
8. 1 cell cycle progression. J. Biol. Chem. (1999) 274(31):22033-22040.
9. LIU A, PRENDERGAST GC: Geranylgeranylated RhoB is sufficient to mediate tissue-specific suppression of Akt kinase activity by farnesyltransferase inhibitors. FEBS Lett. (2000) 481(3):205-208.
10. LIU A, DU W, LIU JP, JESSELL TM, PRENDERGAST GC: RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. (2000) 20(16):6105-6113.
11. JIANG K, COPPOLA D, CRESPO NC et al: The phosphoinositide 3-OH kinase/ AKT2 pathway as a critical target for farnesyltransferase inhibitor-induced apoptosis. Mol. Cell. Biol. (2000) 20(1):139-148.
12. ASHAR HR, JAMES L, GRAY K et al.: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J. Biol. Chem. (2000) 275(39):30451-30457.
13. JOHNSTON SR, HICKISH T, ELLIS P et al.: Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J. Clin. Oncol. (2003) 21(13):2492-2499.
14. KIM ES, KIES MS, FOSSELLA FV et al.: Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer (2005) 104(3):561-569.
15. BERNHARD EJ, McKENNA WG, HAMILTON AD et al.: Inhibiting Ras prenylation increases the radiosensitivity of human rumor cell lines with activating mutations of ras oncogenes. Cancer Res. (1998) 58(8):1754-1761.
16. ZHANG Z, WANG Y, LANTRY LE et al.: Farnesyltransferase inhibitors are potent lung cancer chemopreventive agents in A/J mice with a dominant-negative p53 and/or heterozygous deletion of Ink4a/Arf. Oncogene (2003) 22(40):6257-6265.
17. LIU M, BRYANT MS, CHEN J et al.: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. (1998) 58(21):4947-4956.
18. VAN CUTSEM E, VAN DE VELDE H, KARASEK P et al.: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. (2004) 22(8):1430-1438.
19. TABERNERO J, ROJO F, MARIMON I et al.: Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. (2005) 23(11):2521-2533.
20. IZBICKA E, LAWRENCE R, DAVIDSON K et al.: Activity of a farnesyl transferase inhibitor (SCH66336) against a broad range of tumors taken directly from patients. Proc. Am. Assoc. Cancer Res. (1999) 40:524 (Abstract 3454).
21. 1 pause in sensitive human tumor cell lines. Exp. Cell Res. (2001) 262(1):17-27.
22. SUN SY, ZHOU Z, WANG R, FU H, KHURI FR: The farnesyltransferase inhibitor lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt. Cancer Biol. Ther. (2004) 3(11):1092-1098 (Discussion 1099-1101).
23. BRASSARD DL, ENGLISH JM, MALKOWSKI M et al.: Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp. Cell Res. (2002) 273(2):138-146.
24. REICHERT A, HEISTERKAMP N, DALEY GQ, GROFFEN J: Treatment of Bcr/ Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood (2001) 97(5):1399-1403.
25. PETERS DG, HOOVER RR, GERLACH MJ et al.: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood (2001) 97(5):1404-1412.
26. FELDKAMP MM, LAU N, RONCARI L, GUHA A: Isotype-specific Ras. GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status. Cancer Res. (2001) 61(11):4425-4431
27. BASSO AD, MIRZA A, LIU G et al.: The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. (2005) 280(35):31101-31108.
28. REN H, TAI SK, KHURI F, CHU Z, MAO L: Farnesyltransferase inhibitor SCH66336 induces rapid phosphotylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells. Cancer Res. (2005) 65(13):5841-5847.
29. CHUN KH, LEE HY, HASSAN K et al.: Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells. Cancer Res. (2003) 63(16)4796-4800.
30. TAKADA Y, KHURI FR, AGGARWAL BB: Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-κB-regulated gene expression and up-regulation of apoptosis. J. Biol. Chem. (2004) 279(25):26287-26299.
31. MARCUS AI, ZHOU J, O'BRATE A et al.: The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. (2005) 65(9):3883-3893.
32. KHURI FR, GLISSON BS, KIM ES et al.: Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin. Cancer Res. (2004) 10(9):2968-2976.
33. HAN JY, OH SH, MORGILLO F et al.: Hypoxia-inducible factor 1α and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J. Natl. Cancer Inst. (2005) 97(17):1272-1286.
34. SU ZZ, AUSTIN VN, ZIMMER SG, FISHER PB: Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene (1993) 8(5):1211-1219.
35. ZABRENETZKY V, HARRIS CC, STEEG PS, ROBERTS DD: Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer. (1994) 59(2):191-195.
36. RAK J, MITSUHASHI Y, BAYKO L et al.: Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. (1995) 55(20):4575-4580.
37. NIELSEN LL, SHI B, HAJIAN G et al.: Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. Cancer Res. (1999) 59(23):5896-5901.
38. MARTIN JL, BAXTER RC: Oncogenic ras causes resistance to the growth inhibitor insulin-like growth factor binding protein-3 (IGFBP-3) in breast cancer cells. J. Biol. Chem. (1999) 274(23):16407-16411.
39. EDAMATSU H, GAU CL, NEMOTO T, GUO L, TAMANOI F: Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene (2000) 19(27):3059-3068.
40. SUN J, BLASKOVICH MA, KNOWLES D et al.: Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res. (1999) 59(19):4919-4926.
41. LOPREVITE M, FAVONI RE, DE CUPIS A et al.: In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines. Oncol. Rep. (2004) 11(2):407-414.
42. DAVID E, SUN SY, WALLER EK et al.: The combination of the Farnesyl transferase inhibitor (Ionafarnib) and the proteasome inhibitor (bortezomib) induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood (2005) 106(13):4322-9.
43. NAKAJIMA A, TAUCHI T, SUMI M, BISHOP WR, OHYASHIKI K: Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. Mol. Cancer Ther. (2003) 2(3):219-224.
44. HOOVER RR, MAHON FX, MELO JV, DALEY GQ: Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood (2002) 100(3):1068-1071.
45. BISHOP WR, BOND R, PETRIN J et al.: Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells. J. Biol. Chem. (1995) 270(51):30611-30618.
46. ESKENS FA, AWADA A. CUTLER DL et al.: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J. Clin. Oncol. (2001) 19(4):1167-1175.
47. ADJEI AA, ERLICHMAN C, DAVIS JN et al.: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. (2000) 60(7):1871-1877.
48. LIST AF, DEANGELO D, O'BRIEN S et al: Phase I study of continuous oral administration of lonafarnib (Sarasar) in patients with advanced hematologic malignancies. Blood (2002) 100:789a.
49. KIES MS, CLAYMAN GL, EI-NAGGAR AK et al.: Induction therapy with SCH 66336, a farnesyltransferase inhibitor, in squamous cell carcinoma (SCC) of the head and neck. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2001) 20:896 (Abstract).
50. HURWITZ H, AMADO R, PRAGER D et al.: Phase I and clinical pharmacokinetic trial of the farnesyl transferase inhibitor SCH66336 plus gemcitabine in advanced cancer. Proc. Am. Soc. Clin. Oncol. (2000):185a (Abstract 717).
51. HURWITZ H, COLVIN OM, PETROS WP et al.: Phase I and pharmacokinetic study of SCH66336, a novel FPTI, using a 2-week on, 2-week off schedule. Proc. Am. Soc. Clin. Oncol. (1999) 18:156a.
52. AWADA A, ESKENS FA, PICCART M et al.: Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours. Eur. J. Cancer (2002) 38(17):2272-2278.
53. CORTES J, DALEY GQ, TALPAZ M et al.: Pilot study of SCH66336 a farnesyl transferase inhibitor in patients with chronic or accelerator phase resistant or refractory to imanitib. Blood (2002) 100:164a.
54. SHARMA S, KEMENY N, KELSEN DP et al.: A Phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann. Oncol. (2002) 13(7):1067-1071.
55. WINQUIST E, MOORE MJ, CHI KN et al.: A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer. Urol. Oncol. (2005) 23(3):143-149.
56. YANG H, KIES MS, GLISSON B et al.: A Phase II study of Lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). Proc. Am. Soc. Clin. Oncol. (2000) (Abstract 5565 C).
57. FELDMAN E, CORTES J, HOLVOAK T et al.: Continuous oral lonafarnib (Sarasar) for the treatment of patients with myelodysplastic syndrome. Blood (2003) 102:421a.
58. BLUMENSCHEIN G, LUDWIG C, THOMAS G et al.: A randomized Phase III trial comparing lonafarnib/carboplatin/paclitaxel versus carboplatin/ paclitaxed (CP) in chemotherapy-naive patients with advanced or metastatic non-small cell lung cancer (NSCLC). Proceedings from the 11th World Conference on Lung Cancer, Barcelona, Spain (2005) (Abstract O-082).
59. THEODORE C, GEOFFROIS L, VERMORKEN JB et al.: Multicentre EORTC study 16997: feasibility and Phase II trial of farnesyl transferase inhibitor and gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur. J. Cancer (2005) 41(8):1150-1157.
60. LERSCH C, VAN CUSTEM E, AMADO R et al.: Randomized Phase II study of SCH 66336 and gemcitabine in the treatment of metastatic adenocarcinoma of the pancreas. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2001) 20:608.
61. BURESH A, PERENTESIS J, RIMSZA L et al.: Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia. Leukemia (2005) 19(2):308-310.
62. LANCET JE, KARP JE, GOTLIB L et al.: Zarnestra™ (R115777) in previously untreated poor-risk AML and MDS: preliminary results of a Phase II trial. Blood (2002) 100:560a.
63. RAO S, CUNNINGHAM D, DE GRAMONT A et al.: Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J. Clin. Oncol. (2004) 22:3950-3957.